Cargando…

Early Changes in B and Plasma Cell Subsets and Traditional Serological Markers as Predictors of SRI-4 Response to Therapy in Systemic Lupus Erythematosus

OBJECTIVE: With the premise of the hypothesis that early biological responses to therapy for active systemic lupus erythematosus (SLE) portend later clinical improvements, we studied changes in B cell subsets and traditional serological markers in relation to clinical response to standard therapy (S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parodis, Ioannis, Gomez, Alvaro, Lindblom, Julius, Chow, Jun Weng, Doria, Andrea, Gatto, Mariele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096349/ https://www.ncbi.nlm.nih.gov/pubmed/35572992 http://dx.doi.org/10.3389/fmed.2022.852162

Ejemplares similares

Early B Cell and Plasma Cell Kinetics Upon Treatment Initiation Portend Flares in Systemic Lupus Erythematosus: A Post-Hoc Analysis of Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

B Cell Kinetics upon Therapy Commencement for Active Extrarenal Systemic Lupus Erythematosus in Relation to Development of Renal Flares: Results from Three Phase III Clinical Trials of Belimumab
por: Parodis, Ioannis, et al.
Publicado: (2022)

B cells in systemic lupus erythematosus: Targets of new therapies and surveillance tools
por: Parodis, Ioannis, et al.
Publicado: (2022)

Biomarkers in Neuropsychiatric Systemic Lupus Erythematosus: A Systematic Literature Review of the Last Decade
por: Lindblom, Julius, et al.
Publicado: (2022)

In-/off-label use of biologic therapy in systemic lupus erythematosus
por: Gatto, Mariele, et al.
Publicado: (2014)

Obesity is associated with pain and impaired mobility despite therapy in systemic lupus erythematosus
por: Borg, Alexander, et al.
Publicado: (2023)

Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2021)

Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2019)

Current Insights on Biomarkers in Lupus Nephritis: A Systematic Review of the Literature
por: Palazzo, Leonardo, et al.
Publicado: (2022)

Impact of remission and low disease activity on health-related quality of life in patients with systemic lupus erythematosus
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Systematic literature review informing the EULAR recommendations for the non-pharmacological management of systemic lupus erythematosus and systemic sclerosis
por: Parodis, Ioannis, et al.
Publicado: (2023)

EQ-5D full health state after therapy heralds reduced hazard to accrue subsequent organ damage in systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2022)

EQ-5D-3L full health state discriminates between drug and placebo in clinical trials of systemic lupus erythematosus
por: Lindblom, Julius, et al.
Publicado: (2021)

Patient-Reported Outcomes in Systemic Lupus Erythematosus. Can Lupus Patients Take the Driver’s Seat in Their Disease Monitoring?
por: Parodis, Ioannis, et al.
Publicado: (2022)

Impact of Belimumab on Patient-Reported Outcomes in Systemic Lupus Erythematosus: Insights from Clinical Trials and Real-World Evidence
por: Gomez, Alvaro, et al.
Publicado: (2023)

Clinical Heterogeneity, Unmet Needs and Long-Term Outcomes in Patients with Systemic Lupus Erythematosus
por: Sjöwall, Christopher, et al.
Publicado: (2022)

Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
por: Nikolopoulos, Dionysis, et al.
Publicado: (2023)

B Cell Therapy in Systemic Lupus Erythematosus: From Rationale to Clinical Practice
por: Parodis, Ioannis, et al.
Publicado: (2020)

Fatigue in Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Comparison of Mechanisms, Measures and Management
por: Dey, Mrinalini, et al.
Publicado: (2021)

Diagnosis and management of lung involvement in systemic lupus erythematosus and Sjögren’s syndrome: a literature review
por: Depascale, Roberto, et al.
Publicado: (2021)

Use of Antimalarial Agents Is Associated with Favourable Physical Functioning in Patients with Systemic Lupus Erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Effect of Belimumab on Preventing de novo Renal Lupus Flares
por: Parodis, Ioannis, et al.
Publicado: (2023)

Lupus nephritis: clinical presentations and outcomes in the 21st century
por: Gasparotto, Michela, et al.
Publicado: (2020)

Impact of overweight and obesity on patient-reported health-related quality of life in systemic lupus erythematosus
por: Gomez, Alvaro, et al.
Publicado: (2020)

Autoantibody and Cytokine Profiles during Treatment with Belimumab in Patients with Systemic Lupus Erythematosus
por: Parodis, Ioannis, et al.
Publicado: (2020)

Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus
por: Katsuyama, Takayuki, et al.
Publicado: (2018)

How Can We Enhance Adherence to Medications in Patients with Systemic Lupus Erythematosus? Results from a Qualitative Study
por: Emamikia, Sharzad, et al.
Publicado: (2022)

Anti-dsDNA Antibody Isotypes in Systemic Lupus Erythematosus: IgA in Addition to IgG Anti-dsDNA Help to Identify Glomerulonephritis and Active Disease
por: Villalta, Danilo, et al.
Publicado: (2013)

COVID-19 vaccine safety during pregnancy in women with systemic lupus erythematosus
por: Giannopoulou, Nefeli, et al.
Publicado: (2023)

Systemic Lupus Erythematosus in India: A Clinico-Serological Correlation
por: Mathur, Rachita, et al.
Publicado: (2022)

Monocyte subsets involved in the development of systemic lupus erythematosus and rheumatoid arthritis
por: Hirose, Sachiko, et al.
Publicado: (2019)

Serology of Lupus Erythematosus: Correlation between Immunopathological Features and Clinical Aspects
por: Cozzani, Emanuele, et al.
Publicado: (2014)

Serologic features of cohorts with variable genetic risk for systemic lupus erythematosus
por: Bhattacharya, Jyotsna, et al.
Publicado: (2018)

Systemic Lupus Erythematosus Presented with Bilateral Orbital Edema and Negative Serology
por: Al-Khaldi, Manal, et al.
Publicado: (2019)

Serum cytokines to predict systemic lupus erythematosus clinical and serological activity
por: Moreno‐Torres, Victor, et al.
Publicado: (2022)

Serological comparison of systemic lupus erythematosus with neuropsychiatric lupus using synthetic nucleic acid antigens
por: Khatri, Sangita, et al.
Publicado: (2020)

Predictors of major infections in systemic lupus erythematosus
por: Ruiz-Irastorza, Guillermo, et al.
Publicado: (2009)

Altered peripheral lymphocyte subsets in untreated systemic lupus erythematosus patients with infections
por: Lu, Zhimin, et al.
Publicado: (2019)

Aberrant expansion of follicular helper T cell subsets in patients with systemic lupus erythematosus
por: Jin, Xin, et al.
Publicado: (2022)

Expansion of extrafollicular B and T cell subsets in childhood-onset systemic lupus erythematosus
por: Baxter, Ryan M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_st9u4eqld10rip9gpmdem97ip8